Akcea Therapeutics (AKCA) Misses Q3 EPS by 8c

Akcea Therapeutics (NASDAQ: AKCA) reported Q3 EPS of ($0.27), $0.08 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $13.4 million versus the consensus estimate of $11.91 million.

For earnings history and earnings-related data on Akcea Therapeutics (AKCA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79